Hatice Terzi1 
,
Merve Inan?r2
For correspondence:- Hatice Terzi Email: dr.terzi@hotmail.com
Accepted: 27 August 2022 Published: 30 September 2022
Citation: Terzi H, Inan?r M. Bioymifi suppresses Burkitt’s lymphoma cell line proliferation via cell cycle arrest and apoptosis. Trop J Pharm Res 2022; 21(9):1837-1843 doi: 10.4314/tjpr.v21i9.4
© 2022 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Purpose: To find a new treatment alternative for Burkitt’s lymphoma, one of the B cell-derived non-Hodgkin's lymphomas that has an extremely aggressive growth profile with a high mortality rate.
Methods: Bioymifi (death receptor agonist) was administered at various doses to Human Burkitt's Lymphoma Raji cell lines, and cell proliferation was evaluated using XTT analysis. Apoptosis induction and cell cycle analysis were assessed using flow cytometry.
Results: Bioymifi exhibited good cytotoxicity in Raji cell lines with IC50 value of 29.5 µM. Furthermore, results of apoptosis induction and cell cycle analysis indicated that Bioymifi had potent anti-proliferative activity through sub-S cell cycle arrest and stimulation of apoptosis (p < 0.05).
Conclusion: Bioymifi has anticancer potentials against Human Burkitt's Lymphoma Raji cell lines. Further pharmacological studies will be required to establish the mechanism of action.
Archives
News Updates
Fulltext in PDF